Download App

Log in to access Online Inquiry
Company Overview More
Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx and El-Dorado Donor donation and blood unit management systems; Hemasphere software that provides support for blood drive planning; and Donor Doc and e-Donor software to enhance the donor recruitment and retention. In addition, the company offers hospital products comprising TEG diagnostic systems that enables clinicians to assess the coagulation status of a patient at the point-of-care or laboratory setting; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and BloodTrack, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital’s blood bank information system. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
CEO: Simon, Christopher A.
Market: NYSE
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

HAE Haemonetics
59.880+2.280+3.96%
YOY
Do not show
Hide blank lines
(FY)2022/04/02(Q4)2022/04/02(Q3)2022/01/01(Q2)2021/10/02
Assets
Current assets
Cash, cash equivalents and short term investments
34.94% 259.5M 34.94% 259.5M -- 236.88M -31.07% 192.42M
-Cash and cash equivalents
34.94% 259.5M 34.94% 259.5M -- 236.88M -31.07% 192.42M
Receivables
24.95% 159.38M 24.95% 159.38M -- 154.98M -0.16% 141.31M
-Accounts receivable
24.95% 159.38M 24.95% 159.38M -- 154.98M -0.16% 141.31M
Inventory
-9.17% 293.03M -9.17% 293.03M -- 305.74M 5.71% 322.66M
Prepaid assets
-- -- -- -- -- 31.86M 24.76% 42.86M
Other current assets
-- 44.13M -13.59% 44.13M -- -- -- --
Total current assets
9.01% 756.03M 9.01% 756.03M -- 729.46M -8.03% 699.25M
Non current assets
Net PPE
18.81% 258.48M 18.81% 258.48M -- 238.84M -6.93% 223.75M
Goodwill and other intangible assets
-6.54% 777.55M -6.54% 777.55M -- 792.15M 135.76% 805.84M
-Goodwill
0.18% 467.29M 0.18% 467.29M -- 468.2M 118.36% 468.59M
-Other intangible assets
-15.11% 310.26M -15.11% 310.26M -- 323.95M 165.11% 337.25M
Non current deferred assets
-- -- -- -- -- 6.05M 40.83% 6.06M
Other non current assets
-4.53% 67.67M -11.99% 67.67M -- 64.88M -6.7% 66.6M
Total non current assets
-2.01% 1.1B -2.01% 1.1B -- 1.1B 67.54% 1.1B
Total assets
2.19% 1.86B 2.19% 1.86B -- 1.83B 27.03% 1.8B
Liabilities
Current liabilities
Payables
-- -- -- -- -- 51.18M -8.36% 44.97M
-accounts payable
-- -- -- -- -- 51.18M -8.36% 44.97M
Current accrued expenses
-- -- -- -- -- 39.05M 40.52% 41.07M
Current debt and capital lease obligation
766.15% 214.15M 1158.51% 214.15M -- 144.06M -50.46% 82.73M
-Current debt
1158.51% 214.15M 1158.51% 214.15M -- 144.06M -50.46% 82.73M
Other current liabilities
181.8% 228.12M -3.54% 228.12M -- 121.13M 28.34% 119.7M
Current liabilities
74.47% 442.27M 74.47% 442.27M -- 355.41M -14.8% 288.47M
Non current liabilities
Long term debt and capital lease obligation
-25.76% 559.44M -18.99% 559.44M -- 633.12M 135.02% 698.04M
-Long term debt
-18.99% 559.44M -18.99% 559.44M -- 633.12M 135.02% 698.04M
Non current deferred liabilities
-- -- -- -- -- 26.13M 134.48% 24.57M
Other non current liabilities
985.49% 108.6M -24.67% 108.6M -- 85.94M -11.83% 91.86M
Total non current liabilities
-19.97% 668.04M -19.97% 668.04M -- 745.19M 97.84% 814.48M
Total liabilities
2.03% 1.11B 2.03% 1.11B -- 1.1B 47.01% 1.1B
Shareholders'equity
Share capital
-- -- -- -- -- 511K 0.79% 511K
-common stock
-- -- -- -- -- 511K 0.79% 511K
Retained earnings
-- -- -- -- -- 192.65M 23.54% 169.42M
Paid-in capital
-- -- -- -- -- 566.96M -1.86% 558.16M
Gains losses not affecting retained earnings
-- -- -- -- -- -29.35M 23.23% -29.54M
Total stockholders'equity
2.43% 749.42M 2.43% 749.42M -- 730.78M 4.59% 698.55M
Total equity
2.43% 749.42M 2.43% 749.42M -- 730.78M 4.59% 698.55M
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%